Meeting
2017 ASCO Quality Care Symposium
What are the health care costs for chronic lymphocytic leukemia?
Authors
Matthew J. Matasar
Memorial Sloan Kettering Cancer Center, New York, NY
Matthew J. Matasar, Stacey DaCosta Byfield, Cori Blauer-Peterson, Melissa Montez, Carolina Reyes, Anthony Masaquel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy in Quality; Practice of Quality
Track
Cost, Value, and Policy in Quality,Practice of Quality
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 35, 2017 (suppl 8S; abstract 15)
DOI
10.1200/JCO.2017.35.8_suppl.15
Abstract #
15
Poster Bd #
A17
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Quality Care Symposium
Real-world treatment patterns and health care resource utilization (HRU) among patients with chronic lymphocytic leukemia (CLL) by regimen.
First Author: Brad Schenkel
Poster
2017 ASCO Annual Meeting
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).
First Author: Nitin Jain
Poster
2018 ASCO Quality Care Symposium
Impact of novel chronic lymphocytic leukemia drugs on public spending.
First Author: Elena Mow
Poster
2018 ASCO Annual Meeting
Phase 3 zanubrutinib (BGB‑3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
First Author: Peter Hillmen